Thermo Fisher's third quarter 2026 revenue of $12.14B beat estimates driven by 6% organic growth

Thermo Fisher Scientific reported third quarter 2026 results that exceeded analyst expectations on both the top and bottom lines. The performance was characterized by strong organic growth and margin expansion, supported by steady demand in the Laboratory Products and Biopharma Services segment.

Key Highlights

• Revenue grew 9% year-over-year to $12.14 billion, surpassing the consensus estimate of $11.93 billion.
• Organic revenue growth reached 6%, outperforming the 4% expectation as the company capitalized on improved funding environments.
• Adjusted EPS climbed 15% to $6.68, a $0.28 beat against expectations, while adjusted operating margins expanded 120 basis points to 24.5%.
• The Laboratory Products and Biopharma Services segment remained the primary growth engine, with revenue increasing to $6.86 billion from $5.97 billion in the prior-year period.